CN Patent

CN120698983A — 靶向蛋白降解

Assigned to C4 Therapeutics Inc · Expires 2025-09-26 · 1y expired

What this patent protects

本发明提供了用于如本文进一步描述的治疗应用的药物蛋白降解剂和E3泛素连接酶结合剂。

USPTO Abstract

本发明提供了用于如本文进一步描述的治疗应用的药物蛋白降解剂和E3泛素连接酶结合剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN120698983A
Jurisdiction
CN
Classification
—
Expires
2025-09-26
Drug substance claim
No
Drug product claim
No
Assignee
C4 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.